The Importance of Nanopharmaceuticals and Nanomedicines Applications and Properties: A Current Review
Article Sidebar
Main Article Content
Abstract
Nanotechnology is recognized as a new and rapidly developing field in the pharmaceutical and medical fields. The breakthroughs in nanoscience are developing in almost every field of science, and at the same time, nanotechnologies make life easier in terms of science in the modern era. Nanoscience and nanotechnology are developing fields of study that involve structures, devices, and systems with innovative features and functionalities as a result of the arrangement of their atoms on the 1-100 nm scale. This area became the subject of increasing public awareness and debate in the early 2000s. Nanotechnology contributes to nearly every field of science, including physics, materials science, chemistry, biology, computer science, and engineering. Especially in recent years, nanotechnologies have been applied to human health with promising results, especially in the field of cancer therapy. Moreover, in recent years, nanotechnology has become a widely used technology in a wide range of medical and pharmaceutical applications. Drug-delivery systems based on nanoparticle technology have the potential to launch an industrial revolution that might serve as a watershed moment for future pharmaceutical industries. The main aims of developing nanoparticles as a delivery system are to improve bioavailability by increasing solubility and dissolution rate, to target the drug to specific organs, and to control the drug release rate. To fully understand the nature of nanotechnology, it is useful to review the history of discoveries that led to the current understanding of this science. This review summarizes the progress and key principles of nanomedicine, nanopharmaceuticals, nanoscience, and nanotechnology, and also highlights the pre-modern and modern historical ages of discoveries and historical milestones of nanotechnology and nanomedicines.
Article Details
References
Abazari, Somayeh; Shamsipur, Ali; Bakhsheshi-Rad, Hamid Reza; Ismail, Ahmad Fauzi; Sharif, Safian; Razzaghi, Mahmood; Ramakrishna, Seeram; Berto, Filippo (2020). Carbon Nanotubes (CNTs)- Reinforced Magnesium-Based Matrix Composites: A Comprehensive Review. Materials, 13(19), 4421.
Alagona, P. Fenofibric acid: A new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc. Heal. Risk Manag. 2010, 6, 351–362.
Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence. Pharmaceutics. 2022 Apr 18;14(4):883.
Amoabediny G, Haghiralsadat F, Naderinezhad S, Helder MN, Akhoundi Kharanaghi E, Mohammadnejad Arough J, Zandieh-Doulabi B (2018) Overview of preparation methods of polymeric
and lipid-based (niosome, solid lipid, liposome) nanoparticles: a comprehensive review. Int J Polym Mater Polym Biomater 67(6):383–400.
Andrews, P.; Kovacs, M.; Watson, J. The anti-emetic action of the neurokinin1 receptor antagonist CP- 99,994 does not require the presence of the area postrema in the dog. Neurosci. Lett. 2001, 314, 102– 104.
Anselmo, A.; Mitragotri, S. A Review of Clinical Translation of Inorganic Nanoparticles. AAPS J. 2015, 17, 1041–1054.
Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic: An update. Bioeng. Transl. Med. 2019, 4, e10143.
Auerbach, M.; Pappadakis, J.A.; Bahrain, H.; Auerbach, S.A.; Ballard, H.; Dahl, N.V. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am. J. Hematol. 2011, 86, 860–862.
Bailey RE, Smith AM, Nie S (2004) Quantum dots in biology and medicine. Phys E 25(1):1–12.
Balazsovits, J.A.E.; Mayer, L.D.; Bally, M.B.; Cullis, P.R.; McDonell, M.; Ginsberg, R.S.; Falk, R.E. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother. Pharmacol. 1989, 23, 81–86.
Barber, D.J.; Freestone, I.C. An investigation of the origin of the colour of the Lycurgus Cup by analytical transmission electron microscopy. Archaeometry 1990, 32, 33–45.
Barenholz, Y. Doxil®—The first FDA-approved nano-drug: Lessons learned. J. Control. Release 2012, 160, 117–134.
Batist, G.; Ramakrishnan, G.; Rao, C.S.; Chandrasekharan, A.; Gutheil, J.; Guthrie, T.; Shah, P.; Khojasteh, A.; Nair, M.K.; Hoelzer, K.; et al. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared with Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer. J. Clin. Oncol. 2001, 19, 1444–1454.
Bawa R, Barenholz Y, Owen A. The challenge of regulating nanomedicine: Key issues in nanomedicines. In: Braddock M, editor. Nanomedicines: design, delivery and detection. Cambridge: Royal Society of Chemistry; 2016. p. 290–314.
Bawa R, Johnson S (2009) Emerging Issues in Nanomedicine and Ethics. Nanotechnology & Society, p. 207– 223.
Bawa R, Melethil S, Simmons WJ, Harris D (2008) Nanopharmaceuticals—patenting issues and FDA regulatory challenges. Am Bar Assoc SciTech Lawyer 5(2):10–15.
Bawa, R.; Johnson, S. The Ethical Dimensions of Nanomedicine. Med. Clin. N. Am. 2007, 91, 881–887.
Bennett-Woods D (2008) Nanotechnology: Ethics and society. CRC Press, Boca Raton.
Berges, R. Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability. Eur. Urol. Suppl. 2005, 4, 20–25.
Bhowmik D, Gopinath H, Kumar BP, Duraivel S, Kumar KS. Controlled release drug delivery systems. Pharma Innov. 1(10), (2012).
Borgå, O.; Lilienberg, E.; Bjermo, H.; Hansson, F.; Heldring, N.; Dediu, R. Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients. Adv. Ther. 2019, 36, 2825–2837.
Borges BJ, Carminati LS, Fernandes PM, Fernandes AaR. Regulatory framework of nanopharmaceuticals in developing countries: an analysis of the current rules in Brazil. In: Inorganic Frameworks as Smart Nanomedicines. Grumezescu A (Ed.). William Andrew Publishing, MA, USA, 605–639 (2018).
Briggs BD, Knecht MR. Nanotechnology meets biology: peptide-based methods for the fabrication of functional materials. J. Phys. Chem. Lett 3(3), 405–418 (2012).
Bulbake, U.; Doppalapudi, S.; Kommineni, N.; Khan, W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 2017, 9, 12.
Buster, J. Transdermal menopausal hormone therapy: Delivery through skin changes the rules. Expert Opin. Pharmacother. 2010, 11, 1489–1499.
Paviolo, P.R. Stoddart, Gold nanoparticles for modulating neuronal behavior, Nanomaterials (Basel) 7 (2017) 92.
Caldwell, J.R.; Rapoport, R.J.; Davis, J.C.; Offenberg, H.L.; Marker, H.W.; Roth, S.H.; Yuan,W.; Eliot, L.; Babul, N.; Lynch, P.M. Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to-Severe Osteoarthritis Pain: Results from a Randomized, Placebo-Controlled, Double-Blind Trial and an Open-Label Extension Trial. J. Pain Symptom Manag. 2002, 23, 278–291.
Caster, J.; Patel, A.N.; Zhang, T.; Wang, A. Investigational nanomedicines in 2016: A review of nanotherapeutics currently undergoing clinical trials. WIREs Nanomed. Nanobiotechnol. 2017, 9, e1416.
Chan CK, Peng H, Liu G et al. High-performance lithium battery anodes using silicon nanowires. Nat. Nanotechnol. 3(1), 31–35 (2008).
Chang EH, Harford JB, Eaton MAW, Boisseau PM, Dube A, Hayeshi R, Swai H, Lee DS. Nanomedicine: past, present and future–a global perspective. Bioch Bioph Res Co. 2015;468(3):511–7.
Chaplin, S.; Gnanapavan, S. Plegridy for the treatment of RRMS in adults. Prescriber 2015, 26, 29–31.
Chavez, B.; Sopko, M.A.; Ehret, M.J.; Paulino, R.E.; Goldberg, K.R.; Angstadt, K.; Bogart, G.T. An Update on Central Nervous System Stimulant Formulations in Children and Adolescents with Attention- Deficit/Hyperactivity Disorder. Ann. Pharmacother. 2009, 43, 1084–1095.
Choi, M.; Al-Hajeili, M.; Azmi, A. Nab-paclitaxel: Potential for the treatment of advanced pancreatic cancer. Onco. Targets Ther. 2014, 7, 187–192.
Choi, Y.H.; Han, H.-K. Nanomedicines: Current status and future perspectives in aspect of drug delivery and pharmacokinetics. J. Pharm. Investig. 2018, 48, 43–60.
Clarke, P.D.; Adams, P.; Ibáñez, R.; Herzog, C. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminum-adsorbed hepatitis A vaccine in UK travelers. Travel Med. Infect. Dis. 2006, 4, 313–318.
Coccia M, Wang L. Path-breaking directions of nanotechnology-based chemotherapy and molecular cancer therapy. Technol. Forecast. Soc. Change 94, 155–169 (2015).
Conne, P.; Gauthey, L.; Vernet, P.; Althaus, B.; Que, J.U.; Finkel, B.; Glück, R.; Cryz, S.J. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997, 15, 1675–1679.
Connock, M.; Tubeuf, S.; Malottki, K.; Uthman, A.; Round, J.; Bayliss, S.; Meads, C.; Moore, D. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis. Heal. Technol. Assess. 2010, 14, 1–10.
Coyne, D.W. Ferumoxytol for treatment of iron deficiency anemia in patientswith chronic kidney disease. Expert Opin. Pharmacother. 2009, 10, 2563–2568.
Cristina F, Conxita S (2017). Methods for the In Vitro Characterization of Nanomedicines—Biological Component Interaction. Journal of Personalized Medicine 7(1):2.
Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR (2006) Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107(3):459–466.
Dasari, A.; Xue, J.; Deb, S. Magnetic Nanoparticles in Bone Tissue Engineering. Nanomaterials 2022, 12, 757.
Demetzos C. Pharmaceutical Nanotechnology: Fundamentals and
Desai, N. Challenges in Development of Nanoparticle-Based Therapeutics. AAPS J. 2012, 14, 282–295.
Devreese JT. Importance of nanosensors: Feynman’s vision and the birth of nanotechnology. MRS Bull. 32(09), 718–725 (2007).
Diller, L.H. The Run-on Ritalin: Attention Deficit Disorder and Stimulant Treatment in the 1990s. Häst. Cent. Rep. 1996, 26, 12.
Dilnawaz F, Acharya S, Sahoo SK. Recent trends of nanomedicinal approaches in clinics. Int. J. Pharm. 538(1–2), 263–278 (2018).
Drummond, D.C.; Noble, C.O.; Guo, Z.; Hong, K.; Park, J.W.; Kirpotin, D. Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization Strategy. Cancer Res. 2006, 66, 3271–3277.
Duvic, M. Bexarotene and DAB389IL-2 (Denileukin Diftitox, ONTAK) in Treatment of Cutaneous T- Cell Lymphomas: Algorithms. Clin. Lymphoma 2000, 1, S51–S55.
Epstein, N. Preliminary study showing safety/efficacy of nanoss bioactive versus vitoss as bone graft expanders for lumbar noninstrumented fusions. Surg. Neurol. Int. 2015, 6, 318–322.
Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomed. Nanotechnol. Biol. Med. 9(1), 1–14 (2013).
Ezban, M.; Hermit, M.B.; Persson, E. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia®; Rebinyn®). Haemophilia 2019, 25, 154–161.
Farjadian, F.; Ghasemi, A.; Gohari, O.; Roointan, A.; Karimi, M.; Hamblin, M.R. Nanopharmaceuticals and nanomedicines currently on the market: Challenges and opportunities. Nanomedicine 2019, 14, 93– 126.
Farjadian, F.; Ghasemi, A.; Gohari, O.; Roointan, A.; Karimi, M.; Hamblin, M.R. Nanopharmaceuticals and nanomedicines currently on the market: Challenges and opportunities. Nanomedicine 2019, 14, 93 126.
Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Del. Rev. 58(14), 1456–1459 (2006).
Feynman RP. There’s plenty of room at the bottom. Eng. Sci. 23(5), 22–36 (1960).
Flühmann B, Ntai I, Borchard G, Simoens S, Mühlebach S. Nanomedicines: The magic bullets reaching their target? Eur J Pharm Sci. 2019 Feb 1; 128:73-80.
Franco, Y.L.; Vaidya, T.R.; Ait-Oudhia, S. Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer Targets Ther. 2018, 10, 131–141.
Freestone, I.; Meeks, N.; Sax, M.; Higgitt, C. The Lycurgus Cup—A Roman nanotechnology. Gold Bull. 2007, 40, 270–277.
Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; Smith, C.;Marinos, G.; Gonçales, F.L.; Häussinger, D.; Diago,M.; Carosi, G.; Dhumeaux, D.; et al. Peginterferon Alfa-2a plus Ribavirin for ChronicHepatitis C Virus Infection. N. Engl. J.Med. 2002, 347, 975–982.
Fütterer, S.; Andrusenko, I.; Kolb, U.; Hofmeister, W.; Langguth, P. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J. Pharm. Biomed. Anal. 2013, 86, 151–160.
Gao Z, Kennedy AM, Christensen DA, Rapoport NY (2008) Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy. Ultrasonics 48(4):260–270.
Garnock-Jones, K.P. Fosaprepitant Dimeglumine: A Reviewin the Prevention of Nausea and Vomiting Associated with Chemotherapy. Drugs 2016, 76, 1365–1372.
Germain, M.; Caputo, F.; Metcalfe, S.; Tosi, G.; Spring, K.; Åslund, A.K.; Pottier, A.; Schiffelers, R.; Ceccaldi, A.; Schmid, R. Delivering the power of nanomedicine to patients today. J. Control. Release 2020, 326, 164–171.
Gharehbaghi, M.M.; Yasrebi, S. Comparing the Efficacy of two Natural Surfactants, Curosurf and Alveofact, in Treatment of Respiratory Distress Syndrome in Preterm Infants. Int. J. Women’s Health Reprod. Sci. 2014, 2, 245–248.
Gil, P.R.; Hühn, D.; del Mercato, L.L.; Sasse, D.; Parak,W.J. Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds. Pharmacol. Res. 2010, 62, 115–125.
Glantz, M.J.; Jaeckle, K.A.; Chamberlain, M.C.; Phuphanich, S.; Recht, L.; Swinnen, L.J.; Maria, B.; LaFollette, S.; Schumann, G.B.; Cole, B.F.; et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999, 5, 11.
Glück, R.; Mischler, R.; Finkel, B.; Que, J.; Cryz, S.; Scarpa, B. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994, 344, 160–163.
Graur F et al (2011) Ethical Issues in Nanomedicine, MEDITECH 2011. In Vlad S, Ciupa RV (eds),
IFMBE Proceedings 36, pp. 9–12, 2011
Grewal, I.S. Emerging Protein Biotherapeutics; CRC Press: Boca Raton, FL, USA, 2009.
Harris, J.M.; Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2, 214– 221.
Hartrick, C.T.; Manvelian, G. Sustained-release epidural morphine (DepoDurTM): A review. Today’s Ther. Trends. 2004, 22, 33.
Hinton, D.M. Moderna COVID-19 Vaccine EUA Letter of Authorization. US Food Drug Adm. 2020, 18, 564.
Hood, S.; O’Brien, M.; Higgins, R. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease. Nephrol. Nurs. J. 2000, 27, 1122.
Huang, Y.Y. Approval of the first-ever rnai therapeutics and its technological development history. Prog. Biochem. Biophys. 2019, 46, 249.
Huber, F.-X.; Belyaev, O.; Hillmeier, J.; Kock, H.-J.; Huber, C.; Meeder, P.-J.; Berger, I. First histological observations on the incorporation of a novel nanocrystalline hydroxyapatite paste OSTIM® in human cancellous bone. BMC Musculoskelet. Disord. 2006, 7, 50.
Hwang, S.-J.; Kang, H.; Cha, K.-H.; Cho, W.; Park, J.; Park, H.J.; Sun, B.K.; Hyun, S.-M. Cyclosporine A micellar delivery system for dry eyes. Int. J. Nanomed. 2016, 11, 2921–2933.
Iga AM, Robertson JH, Winslet MC, Seifalian AM (2008) Clinical potential of quantum dots. BioMed Res Int 2007(10):76087.
Iijima S (1991) Helical microtubules of graphitic carbon. Nature 354(6348):56–58.
Iyer R, Hsia CC, Nguyen KT. Nano-therapeutics for the lung: state-of the-art and future perspectives. Curr. Pharm. Des. 21(36), 5233–5244 (2015).
J.T. Duskey, et al., In International Review of Neurobiology Vol. 137 (Eds Hari S. Sharma & Aruna Sharma) 1–28, Academic Press, 2017.
Jacobson, I.M.; Brown, R.S.; Freilich, B.; Afdhal, N.; Kwo, P.Y.; Santoro, J.; Becker, S.;Wakil, A.E.; Pound, D.; Godofsky, E.; et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology 2007, 46, 971–981.
Janssen, P. DailyMed—INVEGA-paliperidone tablet, extended release. Daily Med. USA Natl. Libr. Med. 2012, 14, 45–49.
Janssen, P. Invega Sustenna. Food Drug Adm. 2009, 11, 160407.
Kaddar, N.; Vigneault, P.; Pilote, S.; Patoine, D.; Simard, C.; Drolet, B. Tizanidine (Zanaflex). J. Cardiovasc. Pharmacol. Ther. 2011, 17, 102–109.
Kalele SW, Gosavi S, Urbn J, Kulkarni S (2006) Nanoshell particles: synthesis, properties and applications. Curr Sci 91(8):1038–1052.
Karimi M, Mirshekari H, Aliakbari M, Sahandi-Zangabad P, Hamblin MR. Smart mesoporous silica nanoparticles for controlled-release drug delivery. Nanotechnol. Rev. 5(2), 195–207 (2016).
Karimi M, Zangabad PS, Ghasemi A, Hamblin MR. Future perspectives and the global drug delivery systems market. In: Smart Internal Stimulus-Responsive Nanocarriers for Drug and Gene Delivery. (Eds). Morgan & Claypool Publishers, CA, USA (2015).
Karimi M, Zare H, Bakhshian NA et al. Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine 11(5), 513–530 (2016).
Kherlopian AR, Song T, Duan Q, Neimark MA, Po MJ, Gohagan JK, Laine AF (2008) A review of imaging techniques for systems biology. BMC Syst Biol 2(1):74.
Kim, J.; Shin, S. Cost-Effectiveness of Genexol-PMfor TreatingMetastatic Breast Cancer. J. Breast Cancer 2010, 13, 104–110.
Klein, K.; Stolk, P.; De Bruin,M.L.; Leufkens,H.; Crommelin, D.; De Vlieger, J. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations. Eur. J. Pharm. Sci. 2019, 133, 228–235.
Klibanov AL (2006) Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Investig Radiol 41(3):354–362.
Kohane DS (2007) Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 96(2):203– 209.
Krauss, A.C.; Gao, X.; Li, L.; Manning, M.L.; Patel, P.; Fu, W.; Janoria, K.G.; Gieser, G.; Bateman, D.A.; Przepiorka, D.; et al. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. Clin. Cancer Res. 2019, 25, 2685–2690.
Krishna, R.; Webb, M.S.; Onge, G.S.; Mayer, L.D. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J. Pharmacol. Exp. Ther. 2001, 298.
Kruit, W.H.; Suciu, S.; Dreno, B.; Mortier, L.; Robert, C.; Chiarion-Sileni, V.; Maio, M.; Testori, A.; Dorval, T.; Grob, J.-J.; et al. Selection of Immunostimulant AS15 for Active Immunization With MAGE- A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J. Clin. Oncol. 2013, 31, 2413–2420.
Kumar L.A., Pattnaik G., Satapathy B.S., Swapna S., Mohanty D. Targeting to brain tumor: Nanocarrier- based drug delivery platforms, opportunities, and challenges. J Pharm Bioallied Sci. Apr-Jun 2021;13(2):172-177.
L. Jena, E. McErlean, H. McCarthy, Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme, Drug Deliv. Transl. Res. 10 (2020) 304–318.
L. Rigon, et al., Targeting brain disease in MPSII: preclinical evaluation of IDSloaded PLGA nanoparticles, Int. J. Mol. Sci. 20 (2014).
Landewé, R.; Braun, J.; Deodhar, A.; Dougados,M. ; Maksymowych,W.P.; Mease, P.J.; Reveille, J.D.; Rudwaleit, M.; Van DerHeijde, D.; Stach, C.; et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann. Rheum. Dis. 2014, 73, 39–47.
Langer R, Weissleder R. Scientific discovery and the future of medicine. JAMA 313, 135–136 (2015).
Langston, J.R.; DeHaan, A.M.; Huff, T.W. Staged total hip arthroplasty in a patient with hip dysplasia and a large pertrochanteric bone cyst. Arthroplast. Today 2016, 2, 57–61.
Lau, G.K.K.; Piratvisuth, T.; Luo, K.X.; Marcellin, P.; Thongsawat, S.; Cooksley, G.; Gane, E.; Fried, M.W.; Chow, W.C.; Paik, S.W.; et al. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. N. Engl. J. Med. 2005, 352, 2682–2695.
Leonart, L.P.; Tonin, F.S.; Ferreira, V.L.; Fernandez-Llimos, F.; Pontarolo, R. Effectiveness and safety of pegvisomant: A systematic review and meta-analysis of observational longitudinal studies. Endocrine 2018, 63, 18–26.
Liang X-J. Nanopharmaceutics: The Potential Application of Nanomaterials. World Scientific Publishing Co., Pte Ltd, Toh Tuck Link, Singapore (2013).
Lim, E.-A.; Sohn, H.-S.; Lee, H.; Choi, S.-E. Cost-utility of ferric carboxymaltose (Ferinject®) for iron- deficiency anemia patients with chronic heart failure in South Korea. Cost Eff. Resour. Alloc. 2014, 12, 19.
Lin P, Allhoff F (2008) Nanoscience and nanoethics: Defining the disciplines. In: Allhoff F, Lin P, Moor J, Weckert J (eds) Nanoethics: The social & ethical implications of nanotechnology.
Lister, J. Amphotericin B Lipid Complex (Abelcet®) in the treatment of invasive mycoses: The North American experience. Eur. J. Haematol. 1996, 56, 18–23.
Loo C, Lowery A, Halas N, West J, Drezek R (2005) Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 5(4):709–711.
M. Douek, et al., Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG multicentre trial, Ann. Surg. Oncol. 21 (2014) 1237–1245.
M. Salvalaio, et al., Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in Lysosomal storage disorders, PLoS One 11 (2016).
M. Valenza, et al., Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington’s disease mice, EMBO Mol Med 7 (2015) 1547–1564.
MacDougall, I.C.; Comin-Colet, J.; Breymann, C.; Spahn, D.R.; Koutroubakis, I.E. Iron Sucrose: AWealth of Experience in Treating Iron Deficiency. Adv. Ther. 2020, 37, 1960–2002.
Madan, R.P.; Dezzutti, C.; Rabe, L.; Hillier, S.L.; Marrazzo, J.; McGowan, I.; Richardson, B.A.; Herold, B.C.; The Microbicide Trials Network Biomedical Sciences Working Group and the MTN 004 Protocol Team. Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women. Am. J. Reprod. Immunol. 2015, 74, 323–332.
Mann, B.S.; Johnson, J.R.; Cohen, M.H.; Justice, R.; Pazdur, R. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. Oncologist 2007, 12, 1247–1252.
Mansoori, G.; Fauzi Soelaiman, T. Nanotechnology—An Introduction for the Standards Community. J. ASTM Int. 2005, 2, 1–22.
Marya, S.; Ariyanayagam, T.; Chatterjee, B.; Toms, A.P.; Crawford, R. A Prospective Study of the Efficacy of Vitoss (Beta Tricalcium Phosphate) as a Bone Graft Substitute for Instrumented Posterolateral Lumbar Fusions. Spine J. 2017, 17, S23.
McGahan, L. Continuous erythropoietin receptor activator (Mircera) for renal anemia. Issues Emerg. Health Technol. 2008, 11, 1544.
Mease, P.J.; Fleischmann, R.; Deodhar, A.; Wollenhaupt, J.; Khraishi, M.; Kielar, D.; Woltering, F.; Stach, C.; Hoepken, B.; Arledge, T.; et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann. Rheum. Dis. 2014, 73, 48–55.
Melamed-Gal, S.; Loupe, P.; Timan, B.; Weinstein, V.; Kolitz, S.; Zhang, J.; Funt, J.; Komlosh, A.; Ashkenazi, N.; Bar-Ilan, O.; et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. Neurol. Sci. 2018, 12, 19–30.
Meo, S.A.; Bukhari, I.A.; Akram, J.; Meo, A.S.; Klonoff, D.C. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech andModerna Vaccines. Eur. Rev. Med. Pharmacol. Sci. 2021, 25, 1663–1669.
Mühlebach, S. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach? Adv. Drug Deliv. Rev. 2018, 131, 122–131.
Müller, R.H.; Junghanns, J.-U.A.H. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 2008, 3, 295–309.
Munawar, et al., Nanosensors for diagnosis with optical, electric and mechanical transducers, RSC Adv. 9 (2019) 6793–6803.
Musaji, N. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int. J. Nanomed. 2009, 4, 185–192.
Narayan, R.; Pednekar, A.; Bhuyan, D.; Gowda, C.; Nayak, U.Y. A top-down technique to improve the solubility and bioavailability of aceclofenac: In vitro and in vivo studies. Int. J. Nanomed. 2017, 12, 4921–4935.
National Nanotechnology Initiative (NNI). Available online: www.nano.gov (accessed on 22 July 2019).
Nielsen, F.S.; Schmidt, A.S.; Kristensen, A.K.; Nielsen, A.D.; Kristensen, B.K.; Palm, L. Characterisation of recombinant factor IX before and after GlycoPEGylation. Int. J. Pharm. 2020, 588, 119654.
Nikalje AP. Nanotechnology and its applications in medicine. Med. Chem. 5, 81–89 (2015).
Nyborg, A.C.;Ward, C.; Zacco, A.; Chacko, B.; Grinberg, L.; Geoghegan, J.C.; Bean, R.;Wendeler,M.; Bartnik, F.; O’Connor, E.; et al. A Therapeutic Uricasewith Reduced Immunogenicity Risk and Improved Development Properties. PLoS ONE 2016, 11, e0167935.
Oliver, S.E.; Gargano, J.W.; Marin, M.;Wallace, M.; Curran, K.G.; Chamberland, M.; McClung, N.; Campos-Outcalt, D.; Morgan, R.L.; Mbaeyi, S.; et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine—United States, December. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1922–1924.
Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55(3):329–347.
Paradise, J. Regulating Nanomedicine at the Food and Drug Administration. AMA J. Ethic 2019, 21, E347–E355.
Parpura V. Tissue engineering: nanoelectronics for the heart. Nat. Nanotechnol. 11 (9), 738–739 (2016).
Penman, A.D.; Crowder, K.W.; Watkins, W.M. Pegaptanib for Neovascular Age-Related Macular Degeneration. Stud. Every Ophthalmol. 2020, 76, 239–244.
Petre, C.; Dittmer, D.P. Liposomal daunorubicin as treatment for Kaposi’s sarcoma. Int. J. Nanomed. 2007, 2, 277–288.
Pourmand A, Abdollahi M. Current opinion on nanotoxicology. DARU. 2012;20(1):1.
Prasad, M.; Lambe, U.P.; Brar, B.; Shah, I.; Manimegalai, J.; Ranjan, K.; Rao, R.; Kumar, S.; Mahant, S.; Khurana, S.K.; et al. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomed. Pharmacother. 2018, 97, 1521–1537.
Qu X, Alvarez PJ, Li Q. Applications of nanotechnology in water and wastewater treatment. Water Res. 47(12), 3931–3946 (2013).
Ragelle H, Danhier F, Pr´eat V, Langer R, Anderson DG. Nanoparticle based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin. Drug Deliv. 14(7), 851–864 (2017).
Rai, M.F.; Pham, C.T. Intra-articular drug delivery systems for joint diseases. Curr. Opin. Pharmacol. 2018, 40, 67–73.
Reilly RM (2007) Carbon nanotubes: potentialbenefits and risks of nanotechnology in nuclear medicine. J Nucl Med 48(7):1039–1042.
Resnik, D.B.; Tinkle, S.S. Ethical issues in clinical trials involving nanomedicine. Contemp. Clin. Trials 2007, 28, 433–441.
Rizvi SA, Saleh AM (2018) Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J 26(1):64–70.
Rizzieri, D. Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned? Crit. Rev. Oncol. 2016, 105, 5–17.
S. Mizrahy, A. Gutkin, P. Decuzzi, D. Peer, Targeting central nervous system pathologies with nanomedicines, J. Drug Target. 27 (2019) 542–554.
S. Tiwari, V. Atluri, A. Kaushik, A. Yndart, M. Nair, Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics, Int. J. Nanomedicine 14 (2019) 5541 5554.
S.M. Metcalfe, S. Bickerton, T. Neurodegenerative Disease Fahmy, A perspective on cell-based therapy in the new era of cell-free Nano-therapy, Curr. Pharm. Des. 23 (2017) 776–783.
Sawhney A, Condon B, Singh K, Pang S, Li G, Hui D. Modern applications of nanotechnology in textiles. Textile Res. J. 78(8), 731–739 (2008).
Sayes CM, Aquino GV, Hickey AJ. Nanomaterial drug products: manufacturing and analytical perspectives. AAPS J. 19(1), 18–25 (2017).
Schreiber, S. Certolizumab pegol for the treatment of Crohn’s disease. Ther. Adv. Gastroenterol. 2011, 4, 375–389.
Schwenk, M.H. Ferumoxytol: A New Intravenous Iron Preparation for the Treatment of Iron Deficiency Anemia in Patients with Chronic Kidney Disease. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2010, 30, 70–79.
Sheridan,W.; Fox, R.; Begley, C.; Maher, D.; McGrath, K.; Juttner, C.; To, L.; Szer, J.; Mostyn, G. Effect of peripheral-blood progenitor cells mobilised by filgrastim(G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992, 339, 640–644.
Singh R, Lillard JW Jr (2009) Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86(3):215– 223.
Slatopolsky, E.A.; Burke, S.K.; Dillon, M.A. RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 1999, 55, 299–307.
Smith, J.A.; Mathew, L.; Burney, M.; Nyshadham, P.; Coleman, R.L. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model. Gynecol. Oncol. 2016, 141, 357–363.
Soares, S.; Sousa, J.; Pais, A.; Vitorino, C. Nanomedicine: Principles, Properties, and Regulatory Issues. Front. Chem. 2018, 6, 360.
Steen J. Madsen; Seung-Kuk Baek; Amani R. Makkouk; Tatiana Krasieva; Henry Hirschberg (2012). Macrophages as Cell-Based Delivery Systems for Nanoshells in Photothermal Therapy. 40(2), 507–515.
Stephan, J.; Vlekova, V.; Le Deist, F.; Blanche, S.; Donadieu, J.; Basile, G.D.S.; Durandy, A.; Griscelli, C.; Fischer, A. Severe combined immunodeficiency: A retrospective single-center study of clinical presentation and outcome in 117 patients. J. Pediatr. 1993, 123, 564–572.
Swanson, B.J.; Limketkai, B.N.; Liu, T.-C.; Montgomery, E.; Nazari, K.; Park, J.Y.; Santangelo, W.C.; Torbenson, M.S.; Voltaggio, L.; Yearsley, M.M.; et al. Sevelamer Crystals in the Gastrointestinal Tract (GIT). Am. J. Surg. Pathol. 2013, 37, 1686–1693.
Tejada-Berges, T.; Granai, C.; Gordinier, M.; Gajewski, W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev. Anticancer. Ther. 2002, 2, 143–150.
Thassu, D.; Pathak, Y.; Deleers, M. Nanoparticulate Drug-Delivery Systems: An Overview. Nanopart. Drug Deliv. Syst. 2007, 9, 31.
Tinkle, S.; McNeil, S.E.; Mühlebach, S.; Bawa, R.; Borchard, G.; Barenholz, Y.; Tamarkin, L.; Desai,
N. Nanomedicines: Addressing the scientific and regulatory gap. Ann. N. Y. Acad. Sci. 2014, 1313, 35– 56.
Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 2009, 4, 99–105.
Turecek, P.L.; Romeder-Finger, S.; Apostol, C.; Bauer, A.; Crocker-Buqué, A.; Burger, D.A.; Schall, R.; Gritsch, H. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII: C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia 2016, 22, 957–965.
Ulldemolins A., Seras-Franzoso J., Andrade F., Rafael D., Abasolo I., Gener P., et al. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resistance. 2021;4(1):44-68.
Van Helden, H.; Kuijpers, W.; Langerwerf, P.; Langen, R.; Haagsman, H.; Bruijnzeel, P. Efficacy of Curosurf in a rat model of acute respiratory distress syndrome. Eur. Respir. J. 1998, 12, 533–539.
Ventola, C.L. Progress in nanomedicine: Approved and investigational nanodrugs. Pharm. Ther. 2017, 42, 742–755.
Vilella, et al., Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer’s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery, J. Trace Elem. Med. Biol. 49 (2018) 210–221.
Virdi J (2009) Bridging the knowledge gap: Examining potential limits in nanomedicine, Spontaneous Generations: A Journal for the History and Philosophy of Science; Vol 2, No 1 : Frankenstein in Lilliput: Science at the Nanoscale.
Vo TN, Kasper FK, Mikos AG (2012) Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev 64(12):1292–1309.
Wagner, F.E.; Haslbeck, S.; Stievano, L.; Calogero, S.; Pankhurst, Q.A.; Martinek, K.-P. Before striking gold in gold-ruby glass. Nature 2000, 407, 691–692.
Wang, Y.-X.; Hussain, S.; Krestin, G. Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Eur. Radiol. 2001, 11, 2319–2331.
Wappler, F. S1-Leitlinie maligne Hyperthermie. Der Anaesthesist 2018, 67, 529–532.
Wei G., Wang Y., Yang G., Wang Y., Ju R. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics. 2021 Apr 19;11(13):6370-6392.
Weissig V, Guzman-Villanueva D. Nanopharmaceuticals (part 2): products in the pipeline. Int. J. Nanomedicine 10, 1245–1257 (2015).
Weissig V, Guzman-Villanueva D. Nanopharmaceuticals (part 2): products in the pipeline. Int J Nanomed. 2015; 10:1245.
Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int. J. Nanomed. 9, 4357 (2014).
Weng, Y.; Xiao, H.; Zhang, J.; Liang, X.-J.; Huang, Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol. Adv. 2019, 37, 801–825.
West JL, Halas NJ (2000) Applications of nanotechnology to biotechnology: commentary. Curr Opin Biotechnol 11(2):215–217.
Wilson DR, Sen R, Sunshine JC, Pardoll DM, Green JJ, Kim YJ (2018) Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomed Nanotechnol Biol Med 14(2):237 246.
Yang J., Jia C., Yang J. Designing nanoparticle-based drug delivery systems for precision medicine. International Journal of Medical Sciences. 2021;18(13):2943.
Yuan, D.-M.; Lv, Y.-L.; Yao, Y.-W.; Miao, X.-H.;Wang, Q.; Xiao, X.-W.; Yin, J.; Shi, Y.; Shi, M.-Q.; Zhang, X.-W.; et al. Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study. Thorac. Cancer 2012, 3, 341–347.
Zhou, H.; Yan, J.; Chen, W.; Yang, J.; Liu, M.; Zhang, Y.; Shen, X.; Ma, Y.; Hu, X.; Wang, Y.; et al. Population Pharmacokinetics and Exposure–Safety Relationship of Paclitaxel Liposome in Patients with Non-small Cell Lung Cancer. Front. Oncol. 2021, 10, 01731.